

## REVIEW

# Pathogenesis of rhinitis

A. O. Eifan and S. R. Durham

Allergy and Clinical Immunology, Faculty of Medicine, National Heart and Lung Institute, Imperial College London, London, UK

## Clinical & Experimental Allergy

### Summary

Rhinitis is a heterogeneous condition that has been associated with inflammatory responses as in allergic rhinitis but can also occur in the absence of inflammation such as in so-called idiopathic (previously 'vasomotor') rhinitis. Allergic rhinitis affects approximately one in four of the population of westernized countries and is characterized by typical symptoms of nasal itching, sneezing, watery discharge and congestion. The intention of this review is to illustrate key concepts of the pathogenesis of rhinitis. Imbalance in innate and adaptive immunity together with environmental factors is likely to play major roles. In allergic rhinitis, initial allergen exposure and sensitization involves antigen-presenting cells, T and B lymphocytes and results in the generation of allergen-specific T cells and allergen-specific IgE antibodies. On re-exposure to relevant allergens, cross-linking of IgE on mast cells results in the release of mediators of hypersensitivity such as histamine and immediate nasal symptoms. Within hours, there is an infiltration by inflammatory cells, particularly Th2 T lymphocytes, eosinophils and basophils into nasal mucosal tissue that results in the late-phase allergic response. Evidence for nasal priming and whether or not remodelling may be a feature of allergic rhinitis will be reviewed. The occurrence of so-called local allergic rhinitis in the absence of systemic IgE will be discussed. Non-allergic (non-IgE-mediated) rhinitis will be considered in the context of inflammatory and non-inflammatory disorders.

### Correspondence:

Aarif O. Eifan, Allergy and Clinical Immunology, National Heart and Lung Institute, Imperial College London, Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, UK.  
E-mail: a.eifan@imperial.ac.uk  
Cite this as: A. O. Eifan and S. R. Durham, *Clinical & Experimental Allergy*, 2016 (46) 1139–1151.

### Introduction

Rhinitis is a common heterogeneous chronic disorder in both children and adults that is defined as an inflammation of the nasal mucosa and characterized by the presence of one or more nasal symptoms that includes sneezing, itching, nasal discharge and nasal blockage. Allergic rhinitis is the most common form of non-infectious rhinitis that is associated with an IgE-mediated immune response against environmental allergens [1]. There are a number of rhinitis phenotypes that may be classified as shown in Table 1.

The International Study of Asthma and Allergies in Childhood (ISAAC) revealed an increased worldwide trend of rhinitis with an average prevalence of 8–15% in children [2, 3], with a prevalence in the general population ranging from 10% to 40% in industrialized countries [4–7]. Studies of the natural history of rhinitis in children have shown a prevalence of 2.8% and 11.8% at 4 and 18 years of age for non-allergic rhinitis and, respectively, 3.4% and 27.3% for allergic rhinitis. The adjusted prevalence rate in adults was found to be 9.6% for non-allergic rhinitis and 29.8% for allergic

rhinitis. Children with a parental family history of atopic diseases develop symptoms more frequently and at a younger age than those with non-allergic parents. There is a male predominance of allergic rhinitis and female predominance of non-allergic rhinitis during adolescence and in adulthood [5, 8–10]. There is high risk of developing asthma in both children and adults with allergic rhinitis [11, 12].

Allergic rhinitis can be seasonal or perennial based on temporal patterns of symptoms and relevant allergens. The distinction between seasonal and perennial is not globally applicable; hence, the international working group Allergic Rhinitis and its Impact on Asthma (ARIA) has revised the guidelines of allergic rhinitis on the basis of the severity (mild, moderate and severe) and duration (intermittent, persistent) of symptoms [1]. Both approaches are useful and not mutually exclusive. The ARIA approach is particularly applicable in countries where pollinosis occurs all year-round with no defined season or a very prolonged season. The seasonal/perennial approach is more relevant in countries where there are clear-cut seasonal allergen exposures.

Table 1. Rhinitis phenotypes

|                                                                                   |
|-----------------------------------------------------------------------------------|
| Allergic rhinitis                                                                 |
| Allergic rhinitis with systemic sensitization                                     |
| Local allergic rhinitis without systemic sensitization                            |
| Non-allergic rhinitis                                                             |
| Vasomotor rhinitis: irritants triggered, cold air, exercise                       |
| Infectious                                                                        |
| Gustatory (induced by spicy foods)                                                |
| Non-allergic rhinitis with eosinophilic syndrome                                  |
| Occupational rhinitis                                                             |
| Other rhinitis syndromes                                                          |
| Drug-induced rhinitis: rhinitis medicamentosa, oral contraceptives, aspirin/NSAID |
| Oestrogen induced: pregnancy, menstrual cycle related                             |
| Atrophic rhinitis                                                                 |
| Rhinitis associated with auto-immunological disorders (e.g. vasculitis)           |

### Pathogenesis of rhinitis

The nasal cavity is divided by the nasal septum, which is composed of bone and cartilage. The superior, middle and inferior turbinates are located laterally and lined with pseudostratified columnar respiratory epithelium. The nasal mucosa acts as an air conditioner that regulates inhaled air temperature, humidification and cleans the inspired air. The healthy nasal airway epithelium comprises of ciliated cells, mucus-secreting goblet cells and basal cells which represent 50–90% of airway epithelial cell population. The epithelium rests on a basement membrane zone and covers submucosal structures, thereby forming the link between environmental exposure and the host immune system [13, 14]. The nasal submucosa comprises serous, mucous and seromucous glands, extensive vascular and neural networks and cellular and extracellular matrix components.

Nasal mucus acts as a barrier against external pathogens and has antioxidant, antiprotease and antimicrobial properties. Major constituents of nasal mucus are the mucins which play an important role in antimicrobial and anti-inflammatory defences, as well as in mucociliary clearance [15, 16]. Ciliated epithelium traps foreign bodies in a thin layer of surface mucus that migrates towards the posterior nasopharynx. During inflammation, mucociliary clearance may be impaired leading to exuberant and excessive collection of mucus manifest as increased anterior and/or posterior nasal discharge. Nasal vascularity provides an optimal homeostatic function, while inflammation leads to increased vascular permeability and engorgement causing significant nasal congestion. Parasympathetic cholinergic nerve stimulation results in mucus production from nasal airway glands which also lead to nasal discharge and congestion. Sympathetic fibres, which mainly follow the blood vessels, release noradrenaline and

neuropeptides, which induce vasoconstriction and increased nasal patency. Sympathetic tone fluctuates throughout the day resulting in increasing/decreasing nasal airway resistance in alternate nostrils every 2–4 h – the phenomenon known as the ‘nasal cycle’ [17, 18].

### Allergic rhinitis

Allergic rhinitis is an IgE-mediated disease, which is predominantly caused by environmental allergen exposure in genetically predisposed individuals, and is partly due to alterations in their immune system. Common allergens implicated in allergic rhinitis are mainly proteins and glycoproteins found in airborne particles. Important allergens causing intermittent or persistent symptoms vary in different parts of the world. In United Kingdom, grass pollinosis is the most common; in North America, ragweed predominates; and in Mediterranean areas, *Parietaria* predominates. Dust mite fecal particles, cockroach residues and animal danders are common perennial allergens that may provoke intermittent or persistent symptoms all year-round in temperate climates. Following inhalation, allergen particles are deposited on the surface of the nasal epithelium with subsequent elution of soluble allergenic proteins and their diffusion into the nasal mucosa.

During the initial sensitization process in allergic rhinitis, several common aeroallergens facilitate allergen access to antigen-presenting cells (APCs) through their protease activities which cleave tight junctions in the airway epithelium and activate epithelial cells. Evidence extrapolated from studies of the bronchial epithelium in asthma suggests that activated/damaged nasal epithelial cells secrete thymic stromal lymphopoietin (TSLP), IL-33, IL-25 and other cytokines and chemokines that affect group 2 innate lymphoid cells (ILC2s) and Th2 T lymphocytes directly or via interaction with APCs located within and below the nasal epithelium [19–21] (Fig. 1). In addition, these epithelial cytokines have recently been shown to be important for the activation of ILC2s that lack T cell receptors and do not express T cell nor other cell lineage markers [22]. ILC2 cells express CRTh2, CD127 (the interleukin-7 receptor) and ST-2, the receptor for IL-33. They preferentially express Th2 cytokines, particularly IL-5 and IL-13, and have the potential to augment local Th2-driven allergic inflammation. APCs that include immature dendritic cells (expressing CD1a, CD11c) and macrophages capture allergens, mature and migrate to the draining lymph nodes, where they present processed allergen to naïve T cells that are subsequently skewed in favour of Th2 T cell development [23–25]. Recently, it has been shown that ILC2s may also modulate and polarize naïve T cells into Th2 cells by producing IL-13 which is necessary for dendritic cells to be trafficked into lymph




Fig. 1. Activated/damaged epithelial cells secrete thymic stromal lymphopoietin (TSLP) and IL-33 that activates dendritic cells directly or through ILC2s which captures antigens, migrates to the draining lymph nodes and presents to naive T cells inducing effector Th2 cells. Allergen-activated Th2 cells in local lymph nodes secrete IL-4 that promotes class switching to IgE production by B cells. Re-exposure of the sensitized allergen leads cross-linking of IgE–FcεRI complexes on DCs, mast cells and basophils activating these cells to release of inflammatory mediators causing classic allergic reactions. Other Th2 cytokines such as IL-5, IL-9 and IL-13 are responsible for propagation and maintaining late-phase allergic inflammation.

nodes and subsequently leads to Th2 cell priming [26, 27]. T cells activated during allergic inflammation proliferate into effector memory allergen-specific Th2 cells that release IL-4, IL-5, IL-9 and IL-13. APCs may also be conditioned by Th2-inducing cytokines such as TSLP to 'preferentially' polarize naive T cells towards Th2 effector phenotypes [28]. Allergen-activated Th2 cells secrete IL-4 that maintains the Th2 cell lineage and recruits more T helper cells into this lineage. Th2 cells also secrete IL-13 and express CD40 ligand (CD40L), which together with IL-4 promotes heavy-chain class switching in B lymphocytes in favour of IgE production. IgE antibodies bind to the high-affinity receptor (FcεRI) on the surface of mast cells, basophils and APCs and sensitize these cells to allergens [29]. On allergen re-exposure, cross-linking of IgE–FcεRI complexes on APCs facilitates allergen uptake by APCs for processing and presentation, while IgE–FcεRI interaction on mast cells and basophils with allergen induces the classic

early-phase allergic reaction (EPR). A proportion of subjects subsequently develop a late-phase inflammatory response (LPR) (Fig. 1).

Allergic rhinitis is an excellent model for studying allergic inflammation, where the triggering factors can clearly be identified, particularly in subjects with seasonal rhinitis who can be monitored in and out of the pollen season. Nasal secretions and mucosal tissue are easily accessible for invasive and non-invasive procedures such as biopsies and collection of nasal secretions for analysing clinical and immunological responses in allergic rhinitis [30–32]. Furthermore, nasal allergen challenge represents an *in vivo* experimental model that has contributed immensely to understanding the underlying mechanisms of allergic rhinitis [33–35].

Nasal allergen challenge results in tissue eosinophilia and an increase in cells expressing Th2 cytokines [36]. More recently, nasal allergen challenge has been shown to result in an increase in T cells that express the

prototypic Th2 chemokine receptor CCR4 [37] and increased numbers of the Th2 transcriptional factors STAT6<sup>+</sup> and GATA3<sup>+</sup> in T cells and an increase in the ratio of GATA3<sup>+</sup>:T-bet<sup>+</sup> T cells in the nasal mucosa compared to healthy individuals [38]. This supports the hypothesis that dysregulation of Th1 transcription factors may at least in part be responsible for the exaggerated Th2 responses observed in allergic rhinitis.

Regulatory T cells (Tregs) represent a distinct subtype of T cells that down-regulate effector T cell responses. They are characterized by the expression of CD25 on their surface and signal through the transcriptional factor forkhead box p3 (FOXP3) and secrete suppressive cytokines such as IL-10 and TGF-beta that crosstalk with dendritic cells to induce tolerance [39, 40]. Regulatory T cells directly suppress effector T cells by a number of mechanisms that include the release of soluble cytokines and via cell-cell contact. They also compete with naive T cells in a physical manner by creating aggregates around DCs *in vitro* and inhibiting their maturation [41]. It has been demonstrated that there is a fine balance of immune response between allergic and healthy controls in that allergen-specific IL-4 secreting Th2 cells predominate mainly in sensitized individuals, while Tregs predominate in healthy controls [42, 43]. This was further demonstrated recently in an *in vivo* human allergen challenge model that revealed a significant increase in dendritic cells that expressed TSLP receptors [19] and a substantial reduction in DC expressing IL-10 in local nasal mucosa of allergic rhinitis individuals compared to healthy controls [44]. These data suggest that Tregs may be defective in their ability to suppress type 2 inflammatory responses in allergic individuals.

#### Early-phase allergic response

Allergen challenge in IgE-sensitized individuals results within minutes in early-phase symptoms such as sneezing and itching followed by rhinorrhoea and nasal blockage which then tend to resolve within 1 h. This response stems from allergen cross-linking complexes of sensitized IgE with FcεRI at the surface of mast cells and basophils leading to degranulation and the release of preformed mediators such as histamine and tryptase, and the *de novo* generation of mediators from the membrane lipid such as cysteinyl leukotrienes (leukotrienes C<sub>4</sub>, D<sub>4</sub> and E<sub>4</sub>) and prostaglandins D<sub>2</sub> [35, 45] (Fig. 2). Histamine elicits itching through H<sub>1</sub> receptors that acts on sensory nerves endings, leading to a systemic reflex, such as a paroxysm of sneezing. Leukotrienes, prostaglandin D<sub>2</sub> and vascular endothelial growth factors cause plasma leakage from blood vessels leading to oedema, pooling of blood in the capacious venous sinusoids and an increase in glandular mucus secretion, all

of which may contribute to sensation of nasal congestion [46, 47].

Human nasal provocation studies with cat and grass allergens have examined the kinetics of local and systemic responses to mucosal allergen exposure [31, 33, 48–50]. It has been demonstrated that nasal fluid trypsinase and histamine levels peak at 5 min indicating immediate activation of local mast cells after allergen exposure followed by subsequent increases in the expression of surface activation markers such as CD63 on circulating basophils.

Murine experimental model of allergic rhinitis has been recently developed to trigger nasal responses without lower airway involvement [51]. These models have recently highlighted the essential role of mast cells and basophils in eliciting sequential or biphasic cascades of events in allergic rhinitis. After activation of tissue mast cells through FcεRI and the release of histamines, basophils are recruited through H<sub>4</sub> receptors to the nasal tissue which are subsequently activated through FcεRI in the nasal mucosa in an allergen-specific manner [51–53]. Furthermore, prostaglandin D<sub>2</sub> has been identified as an important mediator during the EPR that signals through its receptor, CRTh2. Selective blockade of CRTh2 receptors led to the prevention of development of both early- and late-phase responses to intranasal allergen challenge [54].

#### Late-phase allergic response

Predominant late-phase symptoms are nasal blockage and to a lesser extent watery nasal discharge. Depending on patient susceptibility and allergen dose, allergic individuals go on to develop a late-phase nasal allergic response. In contrast to the lung, nasal late responses are manifest largely as continuous symptoms and falls in peak nasal inspiratory flow at 4–12 h (Fig. 2). Mediators released during the EPR mainly histamine, PDG<sub>2</sub> and leukotrienes induce the influx and activation of various inflammatory cells leading to late-phase response [30, 55]. Influx of inflammatory cells towards the nasal mucosa is facilitated by adhesion molecules such as vascular cell adhesion molecule 1, E-selectin and intercellular adhesion molecule 1 that promote adherence of circulating eosinophils to endothelial cells. Chemoattractants and cytokines such as IL-5 promote the infiltration of eosinophils, basophils and T cells from the systemic circulation into the nasal submucosa [56–58]. Recently, circulating ILC2s have been shown to increase following nasal allergen provocation and during seasonal allergen exposure in allergic rhinitis compared to healthy subjects. ILC2s represent alternative Th2 cytokine-producing cells in addition to mast cells, basophils and T cells that may contribute to ongoing nasal allergic inflammation [59, 60].




Fig. 2. Summary of mechanisms associated with early-phase allergic reaction (EPR) and late-phase inflammatory response (LPR) during the nasal allergen challenge in allergic rhinitis. Mediators released during the EPR (histamine, PDG2 and leukotrienes – blue and brown circles) induce influx and activation of inflammatory cells. Chemoattractants, histamine receptors and cytokines such as IL-5 released by effector cells during the EPR promote the infiltration of eosinophils, basophils and T cells from the systemic circulation into the nasal submucosa. Cytokines released from basophils, mast cells and Th2 cells such as IL-4, IL-5, IL-9 and IL-13 play an important role in the late-phase response. NAC, Nasal allergen challenge; PD2, prostaglandin 2.

Immunohistochemistry of nasal turbinate biopsies from patients with allergic rhinitis obtained 6 h after allergen challenge or during natural exposure has revealed increased expression of the lymphocyte chemokine receptors CCR3, CCR4, infiltration by eosinophils and elevated levels of cells expressing mRNA for IL-4 and IL-5 [36, 37, 61–63]. Furthermore, induction of rhinitis symptoms after grass pollen nasal allergen challenge showed an increase in activation markers expressed on peripheral blood basophils, plasmacytoid dendritic cells and memory T cells at 6 h indicating induction of not only local but also systemic events reflecting *in vivo* activation of Th2 cells [48]. Cytokines released from basophils, mast cells and Th2 cells such as IL-4, IL-5, IL-9 and IL-13 play an important role in the late-phase response. Recently, it has been demonstrated that there is an inverse correlation between both

IL-5 and IL-13 with nasal patency post-challenge [31, 49]. Both IL-5 and IL-4 play central roles in eosinophil recruitment and activation leading to mucosal influx and the release of granule-derived positively charged proteins such as major basic protein, eosinophil cationic protein and eosinophil peroxidase. These are known to be toxic to respiratory epithelium promoting increased oxidative stress leading to epithelial injury and tissue damage. This in turn leads to the release of epithelial-derived chemokines, cytokines and growth factors that facilitate persistence of late-phase responses and ongoing allergic inflammation [55, 64, 65]. IL-13 shares many activities with IL-4 including usage of a common receptor subunit (IL-4R $\alpha$ -chain). IL-13 is released from mast cells, basophils and ILC2s and promotes B cells to switch in favour of IgE synthesis [66–68]. Collectively, mobilization of effector cells may contribute to the

inflammatory features seen during late-phase responses (Fig. 2).

### *Priming effect*

Some allergic rhinitis subjects begin experiencing nasal symptoms just a few days after the onset of the pollen season, while others have increasingly severe symptoms towards the end of the pollen season despite decreasing aeroallergen levels [69]. This phenomenon is termed *priming effect* in that the allergen dose needed to elicit nasal symptoms decreases with the repetitive natural allergen exposure [70]. Thus, the birch pollen season may 'prime' the nasal mucosa in dual-sensitive patients for a vigorous early onset of grass pollen-related symptoms, whereas high peak seasonal pollen counts may prime for persistent symptoms at lower counts towards the end of the season [71]. This was also observed following nasal provocation when 3-day repetitive allergen challenge using ragweed induced increased nasal symptoms on sequential nasal challenges which were associated with an increase in mediator release from the influx of inflammatory cells [72]. Furthermore, recently [73] it has been demonstrated that on localized unilateral repetitive nasal allergen challenge, there is an increase in nasonasal reflex and nasal-ocular symptoms with an increase in the inflammatory response after each allergen challenge supporting the existence of priming in response to local nasal allergic inflammation. Both inflammatory cells and nasal symptoms were effectively reduced after pre-treatment with intranasal corticosteroids, as a consequence of inhibition of nasal priming. The concept of priming has provided a rationale for the early pre-seasonal introduction of intranasal steroids in the treatment of seasonal allergic rhinitis in order to prevent prolonged late-phase responses that could otherwise lead to progressive inflammation of the nasal mucosa that underlies the priming effect [73–75].

### *Remodelling*

Chronic inflammation is considered to be key factor that leads to tissue structural remodelling [76, 77]. Upper and lower respiratory airways possess a similar respiratory epithelium and comparable Th2-driven IgE-dependent inflammation that underlies the induction of allergic respiratory symptoms. Whereas airway inflammation and remodelling are characteristic of asthma, the presence/absence and extent of tissue remodelling in the upper airways in allergic rhinitis are controversial [78, 79].

A recent study looked into epithelial-to-mesenchymal transition process in rhinitis which is believed to

play an important role in inducing remodelling in asthma and other chronic airway diseases. No alteration in epithelial dedifferentiation in terms of expression of E-cadherin, cytokeratins, MUC5AC<sup>+</sup> goblet cells and p63<sup>+</sup> basal cells was observed, either at protein or mRNA levels between allergic rhinitis sufferers and healthy controls [80]. It has been suggested that these differences between upper and lower allergic airways may occur as a consequence of their different embryologic origin [81]. A recent study explored morphologic and immunohistochemical evidence of remodelling in patients with severe persistent allergic rhinitis (ARIA classification) compared to normal healthy controls. It was shown that despite severe nasal symptoms and the presence of persistent upper airway allergic inflammation, there was no evidence of associated upper airway structural remodelling, as judged by the morphological features of the epithelium and basement membrane zone, nor by the appearances of the nasal blood vasculature and lymphatic vessels. Similarly, there was no evidence of excess collagen deposition in the nasal mucosa compared to healthy controls [82] (Fig. 3). These data suggest that whereas Th2-driven allergic inflammation is a feature of allergic rhinitis, the lack of evidence for remodelling in the same subjects provides limitations on the concept of the 'united airway' and question whether a causal link exists between allergic rhinitis and asthma. These findings are consistent with the findings of two recent randomized controlled trials [83, 84] that showed that treating rhinitis with intranasal corticosteroids in asthma effectively treats their rhinitis symptoms while having no impact on their asthma control.

### *Influence of treatment on allergic rhinitis*

Avoidance of environmental allergens such as dust mites, pets and certain medications and irritants may reduce rhinitis symptoms. However, it is challenging and not feasible to consistently avoid outdoor allergens such as pollen and moulds. Recent meta-analyses showed available environmental/chemical interventions (e.g. acaricides, impermeable bed covers) are not effective [85, 86].

Current treatment for controlling allergic rhinitis symptoms involves antihistamines and corticosteroids. Intranasal steroids are the most effective available medication that suppress all rhinitis symptoms including nasal blockage. It has been demonstrated that intranasal steroids decrease eosinophil infiltration with suppression of local nasal mucosal IL-4 mRNA and IL-5 mRNA expressing cells in seasonal rhinitis compared to placebo as determined by *in situ* hybridization (Fig. 4a) [87, 88].




Fig. 3. Th2 cytokine (IL-4, IL-5, IL-13) levels from nasal lavage comparing persistent allergic rhinitis and healthy controls (a–c). Blood and lymphatic vessels, and collagen area stained using immunohistochemistry (d–f/g–i), respectively, comparing persistent allergic rhinitis (PAR) and controls. Data and pictures adapted from reference 82.

Allergen immunotherapy is currently accepted as the only mode of treatment that can reduce allergic rhinitis symptoms and modify the disease which is associated with production of functional blocking allergen-specific IgG4 [89–91]. Grass pollen immunotherapy decreases seasonal influx of eosinophils with the reduction in IL-5 mRNA expression in local nasal mucosa and a reduction in symptoms [92, 93]. Furthermore, allergen immunotherapy induces local IFN- $\gamma$  and IL-10 mRNA with an increase in IFN- $\gamma$ /IL-5 ratio in nasal mucosa which is accompanied by clinical improvement [94, 95] (Fig. 4b).

### Local allergic rhinitis

Local production of IgE in the nasal mucosa is well documented in allergic rhinitis individuals who have raised serum-specific IgE and positive skin prick tests to clinically relevant allergens [96–99]. There is a small proportion of allergic rhinitis sufferers who get typical allergic symptoms on allergen exposure in the absence of evidence of systemic IgE sensitization as reflected by negative skin prick tests to a panel of common aeroallergens and absence of circulating allergen-specific IgE antibodies to clinically relevant allergens. First,




Fig. 4. a) Effect of intranasal steroids on allergic rhinitis nasal mucosa and inflammation during peak season. PL, placebo; INS, intranasal steroids; EG2: monoclonal antibody that recognizes activated eosinophils. (b) Effect of specific allergen immunotherapy (SIT) on allergic rhinitis nasal mucosa and inflammation during peak season. PL, Placebo; SIT, specific allergen immunotherapy; EG2: monoclonal antibody that recognizes activated eosinophils. (c-e) Pictures depicting nasal mucosal eosinophils, IL-5 mRNA and IL-10 mRNA positive cells using immunochemistry and in situ hybridization staining technique, respectively. Data adapted from references 87, 88, 94 and 95. #: Numbers.

evidence of local allergic rhinitis (LAR) was reported by Huggins and Brostoff [100] who demonstrated positive nasal allergen provocation tests with house dust mite extract in individuals with typical allergic symptoms and negative skin prick tests to mite. A number of studies have since confirmed this condition where allergic

responses are confined to the target organ in the absence of evidence of systemic atopy [101–103].

For example, in studies involving non-atopic subjects who underwent nasal allergen challenge, patients developed rhinitis symptoms after exposure to a variety of allergens including house dust mite (HDM), grass and

olive pollen accompanied by positive objective measures such as changes in acoustic rhinometry and anterior rhinomanometry [104–106]. It has been suggested that up to 47% of so-called idiopathic rhinitis, sufferers may have LAR [107], whereas others have suggested that the incidence may be much lower [101]. In the study by Rondon et al., local inflammatory biomarkers such as tryptase peaked at 15 min and eosinophilic cationic protein significantly increased at 15 min and remained elevated for 24 h after challenge in half of the LAR patients. Local grass pollen and HDM-specific IgE were also found to be increased from nasal secretions in 21–30% of these LAR patients following nasal allergen challenge [106, 108]. Currently, there are no studies that demonstrate local production of tissue-specific IgE<sup>+</sup> B cells or memory B cells in LAR individuals as has previously been demonstrated as the local source of IgE in typical allergic rhinitis associated with raised serum IgE [98, 109, 110]. These data suggest that in subjects who exhibit allergic rhinitis symptoms on allergen exposure without systemic sensitization to a particular allergen, then LAR should be considered in the differential diagnosis and indicate the need for local provocation testing with relevant allergens [111, 112].

### Non-allergic rhinitis

Non-allergic rhinitis is a heterogeneous group of disorders involving chronic symptoms such as sneezing, rhinorrhea, nasal congestion and post-nasal drainage with no obvious allergic trigger from the history, negative skin tests and negative specific IgE against common aeroallergens (Table 1). Non-allergic rhinitis has been classified into inflammatory and non-inflammatory subtypes.

#### *Non-allergic rhinitis with eosinophilia syndrome*

Non-allergic rhinitis with eosinophilia syndrome (NARES) typically comes on in adulthood and is more common in females. It is characterized by persistent rhinitis symptoms of sneezing, congestion, pruritus, occasional loss of smell and profuse watery rhinorrhea. Nasal smears demonstrate increased numbers of eosinophils, typically 5–25% or more of total cell counts [113, 114]. Previous studies of nasal biopsies in NARES have demonstrated increased numbers of mast cells with bound IgE and increased local tryptase levels [115]. Typically, there are no allergic triggers although by current standards the diagnosis of LAR should be explored and the value of local nasal allergen provocation testing considered. However, NARES appears to be a distinct entity that occurs more commonly in females, and is manifested as severe symptoms which are nonetheless steroid responsive. A proportion of such

patients may go on to develop asthma, Samter's triad (asthma, nasal polyps and aspirin sensitivity) or Churg–Strauss syndrome, such that NARES patients should be followed up and monitored long term.

#### *Non-allergic rhinitis without eosinophilia*

This is the most common form of non-allergic/idiopathic rhinitis (formerly termed vasomotor rhinitis) and is a diagnosis of exclusion. The typical clinical presentation is one of mainly clear rhinorrhoea and/or nasal obstruction as dominant symptoms in which allergic disease, sinusitis/nasal polyposis, anatomic abnormalities, pharmacological (iatrogenic), endocrine or known infections have been excluded. Patients have increased sensitivity to environmental triggers such as changes in temperature, air conditioning, pollutants and tobacco smoke and other irritants. In a proportion, emotional stress, sexual arousal and alcohol may be exacerbating factors. Typically, this condition responds poorly to corticosteroids. The pathophysiology underlying this disorder is incompletely understood, but there are some current observations that might lead to a better understanding of this condition [116].

In patients with typical idiopathic non-allergic rhinitis, the local application of capsaicin was effective in suppressing symptoms for up to 6 weeks, whereas there were no changes in local leucocyte populations, including T cells. Conversely, in patients with non-allergic rhinitis, topical corticosteroids reduced T cell numbers but had no impact on symptoms [117, 118].

On unilateral cold dry air nasal challenge, non-allergic rhinitis sufferers showed a crossed nasal lacrimal reflex response with increased nasal secretion on both ipsilateral and contralateral sides to the challenge. This was effectively suppressed by topical atropine application demonstrating the nasoneural reflex mechanisms in rhinitis which may in part be mediated by efferent cholinergic stimulation in response to an environmental stimulus [119–121]. Subjects who were exposed to odours (vanilla, hickory smoke representing distinct and specific olfactory stimuli) underwent functional magnetic resonance imaging. During exposure, there was an increase in blood flow specifically to the odour-sensitive brain regions, suggesting that a neurological response is critically involved in the pathogenesis of NAR [122]. Furthermore, recent results demonstrated that nasal hyper-reactivity is as common in NAR as in AR, but importantly, no inflammatory cells or mediators are present [123]. These data emphasize the non-inflammatory nature of this condition and suggest that in a subgroup of patients with non-allergic rhinitis, neuronal functional abnormalities may be responsible for their symptoms.

## Summary and conclusion

The heterogeneity and multiple aspects of the pathophysiology of rhinitis have been summarized in this review. Recent evidence shows that imbalance in innate and adaptive immunity together with environmental factors are critical in the pathophysiology of rhinitis. The epithelium and its interaction with the newly defined ILC2s through epithelial-derived TSLP and IL-33 cytokines plays a central role in development and progression of nasal inflammation.

Nasal tissue remodelling does not seem to be a feature of allergic rhinitis. There is a need to continue to explore the link between innate and adaptive immunity in allergic rhinitis that might shed light on newer and better treat-

ments for allergic rhinitis. More studies of local allergic (LAR) and non-allergic rhinitis (NARES/NARS) are needed to shed light on mechanisms underlying different pathophysiology of chronic non-allergic rhinitis that could lead to patient-tailored diagnosis and treatment.

## Acknowledgment

We would like to thank Dr Mikila Jacobson for her scientific contribution and sharing some data and figures used in this review.

## Conflict of interest

The authors declare no conflict of interest.

## References

- Bousquet J, Khaltayev N, Cruz AA *et al.* Allergic rhinitis and its impact on asthma ARIA 2008 update in collaboration with the World Health Organization, GA2LEN and AllerGen. *Allergy* 2008; **63**:8–160.
- Ant K, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood ISAAC Phase Three. *Allergy* 2009; **64**:123–48.
- Bjorksten B, Clayton T, Ellwood P, Stewart A, Strachan D. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. *Pediatr Allergy Immunol* 2008; **19**:110–24.
- Singh K, Axelrod S, Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988–1994. *J Allergy Clin Immunol* 2010; **126**:778–83.
- Bachert C, van Cauwenberge P, Olbrecht J, van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. *Allergy* 2006; **61**:693–8.
- Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Respir J* 2004; **24**:758–64.
- Wallace DV, Dykewicz MS, Bernstein DI, *et al.* The diagnosis and management of rhinitis: an updated practice parameter. *J Allergy Clin Immunol* 2008; **122**(2 Suppl.):S1–84.
- Kurukulaaratchy RJ, Karmaus W, Raza A, Matthews S, Roberts G, Arshad SH. The influence of gender and atopy on the natural history of rhinitis in the first 18 years of life. *Clin Exp Allergy* 2011; **41**:851–9.
- Keil T, Bockelbrink A, Reich A *et al.* The natural history of allergic rhinitis in childhood. *Pediatr Allergy Immunol* 2010; **21**:962–9.
- Mølgaard E, Thomsen SF, Lund T, Pedersen L, Nolte H, Backer V. Differences between allergic and nonallergic rhinitis in a large sample of adolescents and adults. *Allergy* 2007; **62**:1033.
- Rochat MK, Illi S, Ege MJ *et al.* Allergic rhinitis as a predictor for wheezing onset in school-aged children. *J Allergy Clin Immunol* 2010; **126**:1170–5.
- Burgess J, Walters EH, Byrnes G *et al.* Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. *J Allergy Clin Immunol* 2007; **120**:863–9.
- Knight DA, Holgate ST. The airway epithelium: structural and functional properties in health and disease. *Respirology* 2003; **8**:432–46.
- Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. *Dis Model Mech* 2010; **3**:545–56.
- Voynow JA, Rubin BK. Mucins, mucus, and sputum. *Chest* 2009; **135**:505–12.
- Williams OW, Sharafkhaneh A, Kim V, Dickey BF, Evans CM. Airway mucus: from production to secretion. *Am J Respir Cell Mol Biol* 2006; **34**:527–36.
- Rosenwasser L. New insights into the pathophysiology of allergic rhinitis. *Allergy Asthma Proc* 2007; **28**:10–5.
- Sarin S, Undem B, Sanico A, Togias A. The role of the nervous system in rhinitis. *J Allergy Clin Immunol* 2006; **118**:999–1016.
- Melum GR, Farkas L, Scheel C, *et al.* A thymic stromal lymphopoietin-responsive dendritic cell subset mediates allergic responses in the upper airway mucosa. *J Allergy Clin Immunol* 2014; **134**:613–21.
- Haenuki Y, Matsushita K, Futatsugi-Yumikura S, *et al.* A critical role of IL-33 in experimental allergic rhinitis. *J Allergy Clin Immunol* 2012; **130**:184–94.
- Licona-Limón P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. *Nat Immunol* 2013; **14**:536–42.
- Neill DR, Wong SH, Bellosi A *et al.* Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. *Nature* 2010; **464**:1367–70.
- Takano K, Kojima T, Go M *et al.* HLA-DR- and CD11c-positive dendritic cells penetrate beyond well-developed epithelial tight junctions in human nasal mucosa of allergic rhinitis. *J Histochem Cytochem* 2005; **53**:611–9.
- Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. House dust mite allergen induces asthma via Toll like receptor 4 triggering of airway structural cells. *Nat Med* 2009; **15**:410–6.

- 25 Jahnsen FL, Gran E, Haye R, Brandt-zaeg P. Human nasal mucosa contains antigen presenting cells of strikingly different functional phenotypes. *Am J Respir Cell Mol Biol* 2004; **30**:31–7.
- 26 Mirchandani AS, Besnard AG, Yip E *et al.* Type 2 innate lymphoid cells drive CD4<sup>+</sup> Th2 cell responses. *J Immunol* 2014; **192**:2442–8.
- 27 Halim TY, Steer CA, Matha L *et al.* Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation. *Immunity* 2014; **40**:425–35.
- 28 Soumelis V, Reche PA, Kanzler H, *et al.* Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. *Nat Immunol* 2002; **3**:673–80.
- 29 Gould HJ, Sutton BJ. IgE in allergy and asthma today. *Nat Rev Immunol* 2008; **8**:205–17.
- 30 Howarth PH, Persson CG, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. *J Allergy Clin Immunol* 2005; **115**(3 Suppl. 1): S414–41.
- 31 Scadding GW, Eifan A, Penagos M *et al.* Local and systemic effects of cat allergen nasal provocation. *Clin Exp Allergy* 2015; **45**:613–23.
- 32 Scadding GW, Eifan A, Lao-Araya M, *et al.* Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge. *Allergy* 2015; **70**:689–96.
- 33 Scadding GW, Calderon MA, Bellido V, *et al.* Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. *J Immunol Methods* 2012; **384**:25–32.
- 34 Terada N, Hamano N, Kim WJ *et al.* The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. *Am J Respir Crit Care Med* 2001; **164**:575–9.
- 35 Naclerio RM, Meier HL, Kagey-Sabotka A *et al.* Mediator release after nasal airway challenge with allergen. *Am Rev Respir Dis* 1983; **128**:597–602.
- 36 Durham SR, Ying S, Varney VA *et al.* Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. *J Immunol* 1992; **148**:2390–4.
- 37 Banfield G, Watanabe H, Scadding G, *et al.* CC Chemokine Receptor 4 (CCR4) in human allergen-induced late nasal responses. *Allergy* 2010; **65**:1126–33.
- 38 Eifan AO, Furukido K, Dumitru A *et al.* Reduced T-bet in addition to enhanced STAT6 and GATA3 expressing T cells contribute to human allergen-induced late responses. *Clin Exp Allergy* 2012; **42**:891–900.
- 39 Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. *Cell* 2008; **133**:775–87.
- 40 Ozdemir C, Akdis M, Akdis CA. T regulatory cells and their counterparts: masters of immune regulation. *Clin Exp Allergy* 2009; **39**:626–39.
- 41 Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S. Foxp3<sup>+</sup> natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. *Proc Natl Acad Sci USA* 2008; **105**:10113–8.
- 42 Akdis M, Verhagen J, Taylor A, *et al.* Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. *J Exp Med* 2004; **199**:1567–75.
- 43 Anderson AE, Mackerness KJ, Aizen M *et al.* Seasonal changes in suppressive capacity of CD4<sup>+</sup> CD25<sup>+</sup> T cells from patients with hayfever are allergen-specific and may result in part from expansion of effector T cells among the CD25<sup>+</sup> population. *Clin Exp Allergy* 2009; **39**:1693–9.
- 44 Pilette C, Jacobson MR, Ratajczak C *et al.* Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. *Allergy* 2013; **68**:312–21.
- 45 Creticos P, Peters S, Adkinson N *et al.* Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. *N Engl J Med* 1984; **310**: 1626–30.
- 46 Peters-Golden M, Gleason MM, Togias A. Cysteinyl leukotrienes: multifunctional mediators in allergic rhinitis. *Clin Exp Allergy* 2006; **36**:689–703.
- 47 Choi GS, Park HJ, Hur GY *et al.* Vascular endothelial growth factor in allergen-induced nasal inflammation. *Clin Exp Allergy* 2009; **39**:655–61.
- 48 Shamji MH, Bellido V, Scadding GW, *et al.* Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals. *Allergy* 2015; **70**:171–9.
- 49 Wagenmann M, Schumacher L, Bachert C. The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. *Allergy* 2005; **60**:1132–8.
- 50 Saini S, Bloom DC, Bieneman A, Vasagar K, Togias A, Schroeder J. Systemic effects of allergen exposure on blood basophil IL-13 secretion and FcεRIβ. *J Allergy Clin Immunol* 2004; **114**:768–74.
- 51 Miyahara S, Miyahara N, Takeda K, Joetham A, Gelfand EW. Physiologic assessment of allergic rhinitis in mice: role of the high-affinity IgE receptor (FcεRI). *J Allergy Clin Immunol* 2005; **116**:1020–7.
- 52 Shiraishi Y, Jia Y, Domenico J *et al.* Sequential engagement of FcεRI on mast cells and basophil histamine H(4) receptor and FcεRI in allergic rhinitis. *J Immunol* 2013; **190**:539–48.
- 53 Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. *Nat Rev Drug Discov* 2008; **7**:41–53.
- 54 Shiraishi Y, Takeda K, Domenico J, Gelfand EW. Role of prostaglandin D2 and CRTH2 blockade in early- and late-phase nasal responses. *Clin Exp Allergy* 2014; **44**:1076–82.
- 55 Westergren VS, Wilson SJ, Penrose JF, Howarth PH, Sampson AP. Nasal mucosal expression of the leukotriene and prostanoid pathways in seasonal and perennial allergic rhinitis. *Clin Exp Allergy* 2009; **39**:820–8.
- 56 Jutel M, Akdis M, Akdis CA. Histamine, histamine receptors and their role in immune pathology. *Clin Exp Allergy* 2009; **39**:1786–800.
- 57 Dobrina A, Menegazzi R, Carlos T *et al.* Mechanisms of eosinophil adherence to cultured vascular endothelial cells: eosinophils bind to the cytokine induced endothelial ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. *J Clin Invest* 1991; **88**:20–6.
- 58 Plewako H, Holmberg K, Oancea I, Gotlib T, Samolinski B, Rak S. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa. *Clin Exp Allergy* 2008; **38**:1124–31.

- 59 Lao-Araya M, Steveling E, Scadding GW, Durham SR, Shamji MH. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. *J Allergy Clin Immunol* 2014; 134:1193–5.e4.
- 60 Doherty TA, Scott D, Walford HH *et al.* Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84. *J Allergy Clin Immunol* 2014; 133: 1203–5.e7.
- 61 Till S, Jopling L, Wachholz P *et al.* T cell phenotypes of the normal nasal mucosa: induction of Th2 cytokines and CCR3 expression by IL-4. *J Immunol* 2001; 166:2303–10.
- 62 Nouri-Aria KT, O'Brien F, Noble W, Jacobson MR, Rajakulasingam K, Durham SR. Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6 h) predominantly by eosinophils. *Clin Exp Allergy* 2000; 30:1709–16.
- 63 Bentley AM, Jacobson MR, Cumberworth V *et al.* Immunohistology of the nasal mucosa in seasonal allergic rhinitis: increases in activated eosinophils and epithelial mast cells. *J Allergy Clin Immunol* 1992; 89:877–83.
- 64 Ayers G, Altman L, McManus M *et al.* Injurious effect of the eosinophil peroxidase–hydrogen peroxidase–halide system and major basic protein on human nasal epithelium in vitro. *Am Rev Respir Dis* 1989; 140:125–31.
- 65 Hogan SP, Rosenberg HF, Moqbel R *et al.* Eosinophils: biological properties and role in health and disease. *Clin Exp Allergy* 2008; 38:709–50.
- 66 Shirakawa I, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM. Atopy and asthma: genetic variants of IL-4 and IL-13 signaling. *Immunol Today* 2000; 21:60–4.
- 67 de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. *J Allergy Clin Immunol* 1999; 103:S492–6.
- 68 Defrance T, Carayon P, Billian G *et al.* Interleukin 13 is a B cell stimulating factor. *J Exp Med* 1994; 179:135–43.
- 69 Norman PS. A rational approach to desensitization. *J Allergy* 1969; 44: 129–45.
- 70 Connell JT. Quantitative intranasal pollen challenges, 3: the priming effect in allergic rhinitis. *J Allergy* 1969; 43:33–44.
- 71 Winther L, Malling HJ, Moseholm L, Mosbech H. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis. I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts. *Allergy* 2000; 55:818–26.
- 72 Wachs M, Proud D, Lichtenstein LM, Kagey-Sobotka A, Norman PS, Naclerio RM. Observations on the pathogenesis of nasal priming. *J Allergy Clin Immunol* 1989; 84:492–501.
- 73 Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. *J Allergy Clin Immunol* 2009; 123:1342–8.
- 74 Pipkorn U, Proud D, Lichtenstein L *et al.* Effect of short-term systemic glucocorticoid treatment on human nasal mediator release after antigen challenge. *J Clin Invest* 1987; 80: 957–61.65.
- 75 Pipkorn U, Proud D, Lichtenstein L, Kagey-Sobotka A, Norman P, Naclerio R. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticoids. *N Engl J Med* 1987; 316:1506–10.
- 76 Bossley CJ, Fleming L, Gupta A *et al.* Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. *J Allergy Clin Immunol* 2012; 129:974–82.
- 77 Van Bruaene N, Derycke L, Perez-Novo CA *et al.* TGF-beta signaling and collagen deposition in chronic rhinosinusitis. *J Allergy Clin Immunol* 2009; 124:253–9.
- 78 Salib RJ, Howarth PH. Remodelling of the upper airways in allergic rhinitis: is it a feature of the disease? *Clin Exp Allergy* 2003; 33:1629–33.
- 79 Watelet JB, Van Zele T, Gjomarkaj M, *et al.* Tissue remodelling in upper airways: where is the link with lower airway remodelling? *Allergy* 2006; 61:1249–58.
- 80 Hupin C, Gohy S, Bouzin C, Lecocq M, Polette M, Pilette C. Features of mesenchymal transition in the airway epithelium from chronic rhinosinusitis. *Allergy* 2014; 69:1540–9.
- 81 Bousquet J, Jacquot W, Vignola A, Bachert C, van Cauwenberge P. Allergic rhinitis: a disease remodeling the upper airways? *J Allergy Clin Immunol* 2004; 113:43–9.
- 82 Eifan AO, Orban NT, Jacobson MR, Durham SR. Severe persistent allergic rhinitis: inflammation but no histologic features of structural upper airway remodeling. *Am J Respir Crit Care Med* 2015; 192(12):1431–9.
- 83 Dahl R, Nielsen LP, Kips J *et al.* Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. *Allergy* 2005; 60:875–81.
- 84 American Lung Association–Asthma Clinical Research Centers' Writing Committee, Dixon AE, Castro M *et al.* Efficacy of nasal mometasone for the treatment of chronic sinonasal disease in patients with inadequately controlled asthma. *J Allergy Clin Immunol* 2015; 135:701–9.
- 85 Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. *Cochrane Database Syst Rev* 2010; (7):CD001563.
- 86 Göttsche PC, Johansen HK. House dust mite control measures for asthma. *Cochrane Database Syst Rev* 2008; (2):CD001187.
- 87 Cameron LA, Durham SR, Jacobson MR *et al.* Expression of IL-4, Cepsilon RNA, and Iepsilon RNA in the nasal mucosa of patients with seasonal rhinitis: effect of topical corticosteroids. *J Allergy Clin Immunol* 1998; 101:330–6.
- 88 Masuyama K, Till SJ, Jacobson MR *et al.* Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. *J Allergy Clin Immunol* 1998; 102(4 Pt 1):610–7.
- 89 Durham SR, Walker SM, Varga EM *et al.* Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; 341:468–75.
- 90 Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. *Curr Opin Allergy Clin Immunol* 2011; 11:586–93.
- 91 Shamji MH, Ljørring C, Francis JN *et al.* Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. *Allergy* 2012; 67:217–26.
- 92 Wilson DR, Irani AM, Walker SM *et al.* Grass pollen immunotherapy

- inhibits seasonal increases in basophils and eosinophils in the nasal epithelium. *Clin Exp Allergy* 2001; 31:1705–13.
- 93 Wilson DR, Nouri-Aria KT, Walker SM *et al.* Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. *J Allergy Clin Immunol* 2001; 107:971–6.
  - 94 Wachholz PA, Nouri-Aria KT, Wilson DR *et al.* Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. *Immunology* 2002; 105:56–62.
  - 95 Nouri-Aria KT, Wachholz PA, Francis JN *et al.* Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. *J Immunol* 2004; 172:3252–9.
  - 96 Durham SR, Gould HJ, Thienes CP *et al.* Expression of epsilon germ-line transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. *Eur J Immunol* 1997; 27:2899–906.
  - 97 Smurthwaite L, Walker SN, Wilson DR *et al.* Persistent IgE synthesis in the nasal mucosa of hayfever patients. *Eur J Immunol* 2001; 31:3422–31.
  - 98 Takhar P, Smurthwaite L, Coker HA *et al.* Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. *J Immunol* 2005; 174:5024–32.
  - 99 KleinJan A, Godthelp T, van Toornenbergen AW, Fokkens WJ. Allergen binding to specific IgE in the nasal mucosa of allergic patients. *J Allergy Clin Immunol* 1997; 99:515–21.
  - 100 Huggins KG, Brostoff J. Local IgE antibodies in allergic rhinitis. *Lancet* 1975; 2:618.
  - 101 Powe DG, Jagger C, Kleinjan A, Carney AS, Jenkins D, Jones NS. “Entopy”: localized mucosal allergic disease in the absence of systemic responses for atopy. *Clin Exp Allergy* 2003; 33:374–9.
  - 102 Powe DG, Huskisson RS, Carney AS *et al.* Mucosal T-cell phenotypes in persistent atopic and nonatopic rhinitis show an association with mast cells. *Allergy* 2004; 59:204–12.
  - 103 Rondón C, Dona I, López S *et al.* Seasonal idiopathic rhinitis with local inflammatory response and specific IgE in absence of systemic response. *Allergy* 2008; 63:1352–8.
  - 104 Wedbäck A, Enbom H, Eriksson NE, Movérare R, Malcus I. Seasonal non-allergic rhinitis (SNAR) – a new disease entity? A clinical and immunological comparison between SNAR, seasonal allergic rhinitis and persistent non-allergic rhinitis. *Rhinology* 2005; 43:86–92.
  - 105 Carney AS, Powe DG, Huskisson RS, Jones NS. Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy? *Clin Exp Allergy* 2002; 32:1436–40.
  - 106 Lopez S, Rondon C, Torres MJ *et al.* Immediate and dual response to nasal challenge with *Dermatophagoides pteronyssinus* in local allergic rhinitis. *Clin Exp Allergy* 2010; 40:1007–14.
  - 107 Rondón C, Campo P, Togias A *et al.* Local allergic rhinitis: concept, pathophysiology, and management. *J Allergy Clin Immunol* 2012; 129:1460–7.
  - 108 Rondon C, Fernandez J, Lopez S *et al.* Nasal inflammatory mediators and specific-IgE production after nasal challenge with grass in local allergic rhinitis. *J Allergy Clin Immunol* 2009; 124:1005–11.
  - 109 Cameron L, Gounni A, Frenkiel S, Lavigne F, Vercelli D, Hamid Q. S epsilon C mu and S epsilon S gamma switch circles in human nasal mucosa following ex vivo allergen challenge: evidence for direct as well as sequential class switch recombination. *J Immunol* 2003; 171:3816–22.
  - 110 Davies JM, Platts-Mills TA, Aalberse RC. The enigma of IgE+ B-cell memory in human subjects. *J Allergy Clin Immunol* 2013; 131:972–6.
  - 111 James LK, Durham SR. Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? *J Allergy Clin Immunol* 2009; 124:1012–3.
  - 112 Campo P, Rondón C, Gould HJ, Barionuevo E, Gevaert P, Blanca M. Local IgE in non-allergic rhinitis. *Clin Exp Allergy* 2015; 45:872–81.
  - 113 Powe DG, Huskisson RS, Carney AS *et al.* Evidence for an inflammatory pathophysiology in idiopathic rhinitis. *Clin Exp Allergy* 2001; 31:864.
  - 114 Ellis A, Keith P. Nonallergic rhinitis with eosinophilia syndrome. *Curr Allergy Asthma Rep* 2006; 6:215–20.
  - 115 Powe DG, Groot Kormelink T, Sisson M *et al.* Evidence for the involvement of free light chain immunoglobulins in allergic and nonallergic rhinitis. *J Allergy Clin Immunol* 2010; 125:139–45.
  - 116 Lieberman P, Pattanaik D. Nonallergic rhinitis. *Curr Allergy Asthma Rep* 2014; 14:439.
  - 117 Van Rijswijk JB, Boeke EL, Keizer JM, Mulder PG, Blom HM, Fokkens WJ. Intranasal capsaicin reduces nasal hyperactivity in idiopathic rhinitis: a double-blind randomized application regimen study. *Allergy* 2003; 58:754–61.
  - 118 Blom HM, Godthelp T, Fokkens WJ, KleinJan A, Mulder PG, Rijntjes E. The effect of nasal steroid aqueous spray on nasal complaint scores and cellular infiltrates in the nasal mucosa of patients with nonallergic, noninfectious perennial rhinitis. *J Allergy Clin Immunol* 1997; 100(6 Pt 1):739–47.
  - 119 Philip G, Jankowski R, Baroody FM, Naclerio RM, Togias AG. Reflex activation of nasal secretion by unilateral inhalation of cold dry air. *Am Rev Respir Dis* 1993; 148(6 Pt 1):1616–22.
  - 120 Jankowski R, Philip G, Togias A, Naclerio R. Demonstration of bilateral cholinergic secretory response after unilateral nasal cold, dry air challenge. *Rhinology* 1993; 31:97–100.
  - 121 Cruz AA, Togias AG, Lichtenstein LM, Kagey-Sobotka A, Proud D, Naclerio RM. Local application of atropine attenuates the upper airway reaction to cold, dry air. *Am Rev Respir Dis* 1992; 146:340–6.
  - 122 Bernstein JA, Hastings L, Boespflug EL, Allendorfer JB, Lamy M, Eliassen JC. Alteration of brain activation patterns in nonallergic rhinitis patients using functional magnetic resonance imaging before and after treatment with intranasal azelastine. *Ann Allergy Asthma Immunol* 2011; 106:527–32.
  - 123 Segboer CL, Holland CT, Reinartz SM *et al.* Nasal hyper-reactivity is a common feature in both allergic and non-allergic rhinitis. *Allergy* 2013; 68:1427–34.